Arcturus Therapeutics Stock Forecast, Price & News

-0.08 (-0.26 %)
(As of 07/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume292,760 shs
Average Volume862,665 shs
Market Capitalization$819.60 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ARCT News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Arcturus Therapeutics logo

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG to develop mRNA therapeutic and vaccine candidates; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.60 out of 5 stars

Medical Sector

917th out of 4,434 stocks

Pharmaceutical Preparations Industry

435th out of 1,734 stocks

Analyst Opinion: 3.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions

Is Arcturus Therapeutics a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 3 sell ratings, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Arcturus Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares.
View analyst ratings for Arcturus Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Arcturus Therapeutics?

Wall Street analysts have given Arcturus Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arcturus Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Arcturus Therapeutics' next earnings date?

Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Arcturus Therapeutics

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) issued its quarterly earnings results on Sunday, May, 9th. The biotechnology company reported ($2.15) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.25) by $0.90. The biotechnology company earned $2.13 million during the quarter, compared to analysts' expectations of $2.94 million. Arcturus Therapeutics had a negative net margin of 1,316.15% and a negative trailing twelve-month return on equity of 43.01%.
View Arcturus Therapeutics' earnings history

How has Arcturus Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARCT stock has increased by 137.9% and is now trading at $31.14.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ARCT?

12 brokerages have issued 12-month price objectives for Arcturus Therapeutics' shares. Their forecasts range from $23.00 to $133.00. On average, they anticipate Arcturus Therapeutics' share price to reach $63.00 in the next year. This suggests a possible upside of 102.3% from the stock's current price.
View analysts' price targets for Arcturus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Arcturus Therapeutics' key executives?

Arcturus Therapeutics' management team includes the following people:
  • Mr. Joseph E. Payne M.Sc., Founder, Pres, CEO & Director (Age 49, Pay $950k)
  • Dr. Padmanabh Chivukula, Founder, Chief Scientific Officer, COO & Sec. (Age 42, Pay $640k)
  • Mr. Andrew H. Sassine, CFO & Director (Age 57, Pay $640k)
  • Mr. Lance Kurata, Chief Legal Officer
  • Dr. Steven George Hughes M.B.A., M.D., Chief Medical Officer (Age 54, Pay $664k)
  • Mr. J.P. Headley, Associate Director of Accounting & Operations
  • Ms. Neda Safarzadeh, Director and Head of Investor Relations/PR & Marketing
  • Ms. Jessica Mendez, Associate Director of HR
  • Mr. Kevin T. Skol, Sr. VP of Bus. Devel. & Alliance Management
  • Mr. Keith C. Kummerfeld CPA, VP of Fin. & Corp. Controller

What is Joe Payne's approval rating as Arcturus Therapeutics' CEO?

9 employees have rated Arcturus Therapeutics CEO Joe Payne on Joe Payne has an approval rating of 90% among Arcturus Therapeutics' employees.

Who are some of Arcturus Therapeutics' key competitors?

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and (SNY).

What is Arcturus Therapeutics' stock symbol?

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcturus Therapeutics' stock price today?

One share of ARCT stock can currently be purchased for approximately $31.14.

How much money does Arcturus Therapeutics make?

Arcturus Therapeutics has a market capitalization of $819.60 million and generates $9.54 million in revenue each year. The biotechnology company earns $-72,150,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis.

How many employees does Arcturus Therapeutics have?

Arcturus Therapeutics employs 118 workers across the globe.

What is Arcturus Therapeutics' official website?

The official website for Arcturus Therapeutics is

Where are Arcturus Therapeutics' headquarters?

Arcturus Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121.

How can I contact Arcturus Therapeutics?

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.